Vertex Pharmaceuticals Inc (VRTX)

Apr 18, 2025

Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next - The Motley Fool

Apr 18, 2025

Apr 17, 2025

Reshma Kewalramani Among TIME’s 100 Most Influential People Of 2025 - IndiaWest

Apr 17, 2025

Apr 17, 2025

Reshma Kewalramani among 2025 Time 100 most influential people - The American Bazaar

Apr 17, 2025

Apr 17, 2025

Peering Into Vertex Pharmaceuticals's Recent Short Interest - Benzinga

Apr 17, 2025

Apr 16, 2025

Reshma Kewalramani named among Time magazine's 100 most influential people - Firstpost

Apr 16, 2025

Apr 15, 2025

Vertex’s Attempt to Redefine AKS Falls Short: Key Insights for Pharma Manufacturers - ArentFox Schiff

Apr 15, 2025

Apr 15, 2025

Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $617 From $615, Maintains Buy Rating - marketscreener.com

Apr 15, 2025

Apr 14, 2025

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis - BioSpace

Apr 14, 2025

Apr 13, 2025

Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF R - GuruFocus

Apr 13, 2025

Apr 12, 2025

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? - AOL.com

Apr 12, 2025

Apr 12, 2025

Lobbying Update: $20,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq

Apr 12, 2025

Apr 11, 2025

Pharma Tariffs Are Coming. Investors Underestimate the Risk. - Barron's

Apr 11, 2025

Apr 11, 2025

Vertex researcher recognized by the Canada Gairdner International Award - Vertex Pharmaceuticals

Apr 11, 2025

Apr 11, 2025

CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades' - Benzinga

Apr 11, 2025

Apr 11, 2025

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canad - GuruFocus

Apr 11, 2025

Apr 11, 2025

Vertex Researcher, Paul Negulescu Ph.D., Receives The 2025 Canada Gairdner International Award For Pioneering Research And Discovery Of Medicines For Cystic Fibrosis - MarketScreener

Apr 11, 2025

Apr 10, 2025

Vertex Pharmaceuticals (VRTX) Stock Moves -1.41%: What You Should Know - Yahoo Finance

Apr 10, 2025

Apr 10, 2025

Vertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) Franchise - MSN

Apr 10, 2025

Apr 09, 2025

Vertex Pharmaceuticals gets EU nod to expand label for cystic fibrosis treatment - MSN

Apr 09, 2025

Apr 09, 2025

‘Put On Your Life Vest’: Pharma Tariffs Are Coming - BioSpace

Apr 09, 2025

Apr 09, 2025

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - MSN

Apr 09, 2025

Apr 09, 2025

Morgan Stanley Adjusts PT on Vertex Pharmaceuticals to $462 From $459, Keeps Equalweight Rating - MarketScreener

Apr 09, 2025

Apr 09, 2025

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 41% Undervalued - Yahoo Finance

Apr 09, 2025

Apr 09, 2025

Vertex CEO Reshma Kewalramani gets 4% pay bump to $21.5M - Fierce Pharma

Apr 09, 2025

Apr 08, 2025

Vertex non-opioid painkiller Journavx gets mixed ICER review - MSN

Apr 08, 2025

Apr 08, 2025

Jim Cramer Calls Vertex Pharmaceuticals Incorporated (VRTX) “Terrific” With “Revolutionary Pain Drug” - Insider Monkey

Apr 08, 2025

Apr 08, 2025

Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Long Term Growth Stock to Buy According to Billionaires? - Yahoo Finance

Apr 08, 2025

Apr 08, 2025

Is Vertex Pharmaceuticals Stock a Buy? - MSN

Apr 08, 2025

Apr 08, 2025

Vertex secures expanded EU approval for Kaftrio - The Pharma Letter

Apr 08, 2025

Apr 08, 2025

VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe - Yahoo Finance

Apr 08, 2025

Apr 07, 2025

Jim Cramer Nailed These 11 Stock Picks - Insider Monkey

Apr 07, 2025

Apr 07, 2025

Vertex to Announce First Quarter 2025 Financial Results on May 5th - BioSpace

Apr 07, 2025

Apr 07, 2025

Vertex Gains European Approval For Expanded Use Of KAFTRIO In Treating Cystic Fibrosis - Nasdaq

Apr 07, 2025

Apr 07, 2025

European Commission Expands Approval for Vertex's Kaftrio (VRTX) - GuruFocus

Apr 07, 2025

Apr 07, 2025

Vertex Pharmaceuticals Says EU Approves Kaftrio Label Expansion in Cystic Fibrosis - MarketScreener

Apr 07, 2025

Apr 07, 2025

EU approves expanded use of Vertex’s cystic fibrosis drug - Investing.com

Apr 07, 2025

Apr 07, 2025

Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers' - Benzinga

Apr 07, 2025

Apr 07, 2025

2 Stocks to Buy if You're Worried About a Recession - Yahoo Finance

Apr 07, 2025

Apr 06, 2025

Vertex Pharmaceuticals: A Look At Their Pain Therapy Program (NASDAQ:VRTX) - Seeking Alpha

Apr 06, 2025

Apr 05, 2025

Vertex Pharmaceuticals - drugdiscoverytrends.com

Apr 05, 2025

Apr 04, 2025

10 Best Health Care Stocks to Buy for 2025 - Money/ US News

Apr 04, 2025

Apr 04, 2025

Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace

Apr 04, 2025

Apr 03, 2025

Bank of America Increases Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $567.00 - MarketBeat

Apr 03, 2025

Apr 03, 2025

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance

Apr 03, 2025

Apr 03, 2025

Vertex Pharmaceuticals: How a Human-Centric Digital Strategy Transforms Supply Chain Agility - Logistics Viewpoints -

Apr 03, 2025

Apr 03, 2025

Wells Fargo Remains a Hold on Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Apr 03, 2025

Apr 03, 2025

Vertex Pharmaceuticals' Human-Centric Approach to Digital Transformation - ARC Advisory

Apr 03, 2025

Apr 03, 2025

Petri Dish: Vertex halts type 1 diabetes trial; Watertown manufacturer sold - The Business Journals

Apr 03, 2025

Apr 02, 2025

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS) - The Globe and Mail

Apr 02, 2025

Apr 02, 2025

Vertex Pharmaceuticals (VRTX): Company Profile, Stock Price, News, Rankings - Fortune

Apr 02, 2025